The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
|Articles|December 14, 2020
Pharmacy Times: Week of December 14 Lineup
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
Advertisement
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:
- A video interview with Emily Cook, JD, a partner with McDermott Will & Emery, about the final 340B dispute resolution rule, which was sent by the Department of Health and Human Services to the Office of Management and Budget for review.
- Continuing coverage of the American Society of Hematology Annual Meeting and Exposition and the American Society of Health-System Pharmacists Midyear 2020 Clinical Meeting and Exhibition.
- Representatives from the Academy of Managed Care Pharmacy student chapter at Nova Southeastern University discuss the challenges of remote learning during the coronavirus disease 2019 pandemic.
Advertisement
Related to this article
Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
EMBER-3 data show switching to the combination at progression nearly doubled PFS versus imlunestrant alone in ESR1-mutated advanced breast cancer.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Target Trial Emulation Finds Limited Survival Benefit With Statins After Colorectal Cancer Treatment
Statin initiation after colorectal cancer treatment was associated with only modest survival differences after investigators accounted for biases that can exaggerate benefits in observational research.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Data Reshapes Nonstatin Lipid Therapy Choices
2
Comparison of Weight-Based vs Non–Weight-Based Norepinephrine Dosing in Patients With Septic Shock
3
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
4
From Evidence to Execution: Pharmacists Navigate MRA Selection and Access in HFpEF and HFmrEF
5